AbbVie will receive royalties on net sales within Greater China. Credit: © AbbVie Inc. All rights reserved.

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500.

The humanised trispecific antibody is undergoing Phase I clinical trials in the US and China in subjects with relapsed or refractory multiple myeloma (MM).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

 Simcere Zaiming will gain an upfront payment from AbbVie and is eligible for option fees and milestone payments that could total up to $1.055bn.

Simcere Zaiming will also obtain tiered royalties on net sales outside Greater China. AbbVie will receive royalties on net sales within the Greater China region.

AbbVie haematology therapeutic area head and vice-president Mariana Cota Stirner stated: “As a leader in haematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless research and development efforts and collaborations.

“We look forward to partnering with Simcere Zaiming to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SIM0500 targets G-protein-coupled receptor class 5 member D (GPRC5D), cluster of differentiation 3 (CD3) and B-cell maturation antigen (BCMA).

Developed using Simcere’s T-cell engager polyspecific antibody technology platform, the therapy has demonstrated strong T-cell cytotoxicity against MM cells.

Simcere Zaiming was founded in 2023 with a focus on oncology and is a subsidiary of Simcere Pharmaceutical Group Limited.

In a separate development, AbCellera has expanded its existing partnership with AbbVie to include the discovery of T-cell engagers (TCE) for oncology applications.

The partnership, which began in December 2022, now provides AbbVie access to AbCellera’s TCE platform for the development of therapeutic antibodies targeting tumours.

AbbVie will have the rights to develop and commercialise any resulting therapeutic antibodies, while discovery activities will be led by AbCellera.

AbCellera will be eligible to receive upfront and research payments, as well as potential milestone payments and tiered royalty payments on net sales.

In February 2024, AbbVie and Tentarix Biotherapeutics entered a strategic partnership agreement to discover and develop conditionally active, multi-specific biologic candidates in the fields of oncology and immunology.